2290. Carbapenem vs. Piperacillin–tazobactam Definitive Therapy for Patients with Bloodstream Infections Due to Ceftriaxone Not Susceptible Escherichia coli or Klebsiella species

BACKGROUND: Definitive therapy with piperacillin–tazobactam (TZP) for ceftriaxone (CRO)-resistant E. coli or K. pneumoniae bloodstream infections (BSI) has been shown to be inferior to carbapenem therapy in a randomized trial. METHODS: The Premier US database was queried for hospitalized patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: MacVane, Shawn H, Bhalodi, Amira A, Spafford, Kyle, Humphries, Romney, Oppermann, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810734/
http://dx.doi.org/10.1093/ofid/ofz360.1968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810734/
http://dx.doi.org/10.1093/ofid/ofz360.1968

Ejemplares similares